Market intelligence, clinical progress, and high-purity reagents for bile acid transport and metabolic disease development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ASBT/SLC10A2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | ASBT/SLC10A2 Lentivirus Premade Particles (full-length ORF, CMV promoter, Puromycin selection, >10⁸ TU/mL) for stable cell line construction enabling functional uptake assays. | View ASBT Products |
| Antigen / Membrane Prep | ASBT/SLC10A2 Transmembrane Protein or Membrane Preparation (HEK293 overexpressing cells, detergent-solubilized, endotoxin <1 EU/μg, MW verified). | View ASBT Products |
| Benchmark Antibody | Anti-ASBT/SLC10A2 Reference Antibody (recombinant positive control for expression validation). | View ASBT Products |
| Validator (siRNA) | ASBT/SLC10A2 siRNA Set (3 unique sequences, HPLC purified, >95% knockdown) for target engagement and specificity verification. | View ASBT Products |
| Counter-Screen | NTCP (SLC10A1) Lentivirus & Membrane Prep for selectivity profiling against hepatic bile acid uptake – mandatory for safety assessment. | View NTCP Products |
| Pathway Partner | FXR (NR1H4) Protein & Reporter Cell Line for combination studies and synergy evaluation. | View FXR Products |
| Ortholog Panel | Cynomolgus (and mouse) ASBT/SLC10A2 ORF Lentivirus for cross-species uptake assay validation (95% homology). | View ASBT Products |
| Related Target A | TGR5 (GPBAR1) – Membrane bile acid receptor mediating systemic metabolic benefits. | View GPBAR1 Products |
| Related Target B | SLC10A3/A4/A6/A7 – Custom membrane preparations for sub-family counter-screening available upon request. | View CUSTOM Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex multi-pass membrane structure; functional uptake assay (sodium-dependent taurocholate transport) requires native conformation. | High-titer ASBT Lentivirus (>10⁸ TU/mL) generates stable HEK293/MDCK lines with surface expression confirmed by flow cytometry. |
| Homolog off-target toxicity (NTCP selectivity). | Human/mouse/cyno ortholog panels for both ASBT and NTCP available with sequence-verified ORFs; selectivity window >100x. |
| Lack of reliable cell models. | Sequence-verified, endotoxin-controlled full-length human and cyno ORF clones; Lentivirus premade particles ready to use. |
| False positives in uptake assays. | Validated siRNA set included for target-specific uptake inhibition confirmation; rescue experiments possible. |
| Sub-family counter screening (SLC10A3, A4, A6, A7). | Custom protein synthesis for entire SLC10 family; strict sequence verification by mass spec. |
| Cross-species translation (preclinical to clinic). | Ortholog panel (human, cyno, mouse) enables multi-species activity profiling. |
Live ASBT/SLC10A2 R&D Tracker
Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (SLC10A2)
- ➤ Ileal Bile Acid Transporter (IBAT) Studies
- ➤ Latest Resistance & Mechanism Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for ASBT (Apical Sodium-Dependent Bile Acid Transporter) therapeutics has evolved significantly. Early efforts in T2DM and PBC met mixed results (Takeda's Volixibat discontinued in PBC/NASH), leading to a pivot toward rare cholestatic diseases where bile acid accumulation is pathogenic. First-generation inhibitors (Odevixibat/Bylvay, Maralixibat/Livmarli) are now approved for PFIC and Alagille syndrome. The competitive landscape now focuses on:
- Indication Refinement: Moving beyond PFIC to Alagille syndrome, severe pruritus, and primary biliary cholangitis (PBC). Next wave targets MASH/NASH and chronic idiopathic constipation.
- Modality Dominance: Small molecule inhibitors remain king (macrocyclic, aminothiazole, benzothiazepine scaffolds), though antisense oligonucleotides (Ionis) and gut-restricted formulations are emerging to minimize systemic exposure and off-target hepatic engagement.
- Biomarker-Driven Trials: Serum C4 (7α-hydroxy-4-cholesten-3-one) and total bile acids as pharmacodynamic markers for target engagement.
- Key Challenge: Balancing efficacy vs. diarrhea tolerability ceiling. Next-generation R&D explores dual FXR/ASBT modulation and bile acid-independent pathways to bypass compensatory hepatic bile acid synthesis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Gut-restricted) | Ipsen (Odevixibat), Mirum (Maralixibat), Novartis (Linerixibat), EA Pharma (Elobixibat) | PFIC, ALGS, Cholestatic Pruritus, Constipation, MASH | Cell-based uptake inhibition assay requiring stable ASBT-expressing lines; need validated sodium-dependent kinetics. |
| Small Molecule (Systemic) | Various biotechs | Constipation, MASH | Selectivity assay against NTCP/SLC10A1 to avoid hepatic toxicity. |
| Antisense Oligonucleotide | Ionis Pharmaceuticals (research phase) | Hypercholesterolemia | Knockdown validation with high-specificity ASBT siRNA. |
| Dual FXR/ASBT Modulator | Undisclosed biotech pipeline | NASH, Metabolic Syndrome | Pathway cross-talk: need both ASBT and FXR reagents for combination index studies. |
| Bile Acid Sequestrant (non-absorbed) | Traditional (Colesevelam) | T2DM (adjunct) | Mechanism differentiation: need ASBT/NTCP selectivity panels to prove specific vs. non-specific bile acid reduction. |
Natural Variants & Polymorphisms Impacting Drug Development
Key polymorphisms in SLC10A2 (UniProt Q12908) have been documented in dbSNP: rs55971546 (VAR_024837), rs60380298 (VAR_024838), and rs188096 (VAR_004613). These variants may alter transporter activity, substrate affinity, or inhibitor binding. When designing ASBT inhibitors, it is critical to confirm that candidate molecules maintain efficacy against common allelic variants. TarMart’s ORF clones are sequence-verified to ensure wild-type reference, and custom mutagenesis services are available for variant-specific screening.